These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Cortellini A; Buti S; Agostinelli V; Bersanelli M Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344 [TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Reynolds KL; Guidon AC Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825 [TBL] [Abstract][Full Text] [Related]
5. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Kottschade LA Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902 [TBL] [Abstract][Full Text] [Related]
6. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy. King GT; Sharma P; Davis SL; Jimeno A Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937 [TBL] [Abstract][Full Text] [Related]
7. [Endocrine Organ Dysfunction with Immune-Checkpoint Inhibitors]. Inaba H; Ariyasu H; Kurimoto C; Iwakura H; Akamizu T Gan To Kagaku Ryoho; 2018 Jul; 45(7):1031-1035. PubMed ID: 30042266 [TBL] [Abstract][Full Text] [Related]
8. [Management of Toxicities of Immune Checkpoint Inhibitors]. Horio Y Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987 [TBL] [Abstract][Full Text] [Related]
9. Do immune-related adverse events correlate with response to immune checkpoint inhibitors? Saleh K; Khalife-Saleh N; Kourie HR Immunotherapy; 2019 Mar; 11(4):257-259. PubMed ID: 30678551 [No Abstract] [Full Text] [Related]
10. Cutaneous adverse effects of the immune checkpoint inhibitors. Collins LK; Chapman MS; Carter JB; Samie FH Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531 [TBL] [Abstract][Full Text] [Related]
11. Endocrine side effects induced by immune checkpoint inhibitors. Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977 [TBL] [Abstract][Full Text] [Related]
12. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. Koster BD; de Gruijl TD; van den Eertwegh AJ Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539 [TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy is cancer treatment with a novel side-effect profile]. Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844 [TBL] [Abstract][Full Text] [Related]
14. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847 [TBL] [Abstract][Full Text] [Related]
15. Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Day D; Hansen AR BioDrugs; 2016 Dec; 30(6):571-584. PubMed ID: 27848165 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772 [TBL] [Abstract][Full Text] [Related]